Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB)

Cancer. 1988 May 15;61(10):1977-82. doi: 10.1002/1097-0142(19880515)61:10<1977::aid-cncr2820611008>3.0.co;2-n.

Abstract

Ninety-eight patients with locally advanced breast cancer (Stage IIIA-IIIB) were entered into a pilot study combining intensive induction (neoadjuvant) chemotherapy (VTMFAP) with or without hormonochemotherapy, external and interstitial radiotherapy, and consolidation chemotherapy with or without hormonochemotherapy. Tumor regression over 50% was observed in 91% patients after chemotherapy, and complete clinical remission occurred in 100% patients after irradiation. The rate of local relapse is 13%. The 3-year disease-free survival is 62% and 3-year global survival is 77%. Initial chemotherapeutic tumor regression greater than 75% is the main predictive factor for disease-free survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brachytherapy
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / therapy*
  • Cobalt Radioisotopes / therapeutic use
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Evaluation Studies as Topic
  • Fluorouracil / administration & dosage
  • Humans
  • Iridium Radioisotopes / therapeutic use
  • Methotrexate / administration & dosage
  • Prednisone / administration & dosage
  • Radioisotope Teletherapy*
  • Remission Induction
  • Tamoxifen / therapeutic use
  • Thiotepa / administration & dosage
  • Vinblastine / administration & dosage

Substances

  • Cobalt Radioisotopes
  • Iridium Radioisotopes
  • Tamoxifen
  • Vinblastine
  • Doxorubicin
  • Thiotepa
  • Fluorouracil
  • Prednisone
  • Methotrexate